We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
-6.97%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.62B
AUM Growth
-$52.9M
Cap. Flow
+$108M
Cap. Flow %
4.11%
Top 10 Hldgs %
34.14%
Holding
89
New
20
Increased
21
Reduced
12
Closed
10

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$86.2M
2
AXSM icon
Axsome Therapeutics
AXSM
+$43M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$40.7M
4
ABBV icon
AbbVie
ABBV
+$37.6M
5
VEEV icon
Veeva Systems
VEEV
+$37.2M

Top Sells

Rank Stock Value
1
OM icon
Outset Medical
OM
+$128M
2
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$34.1M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$24.4M
4
HRTX icon
Heron Therapeutics
HRTX
+$20.1M
5
HCA icon
HCA Healthcare
HCA
+$20.1M

Sector Composition

Rank Sector Weight
1 Healthcare 93.59%
2 Financials 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JNJ icon
1
Johnson & Johnson
JNJ
$609B
$109M 4.16%
615,064
+30,181
+5% +$5.38M
CYTK icon
2
Cytokinetics
CYTK
$11.1B
$96.8M 3.69%
2,465,016
– –
LLY icon
3
Eli Lilly
LLY
$1.04T
$96.8M 3.69%
298,643
– –
CNC icon
4
Centene
CNC
$33.2B
$94.1M 3.59%
1,112,480
– –
JAZZ icon
5
Jazz Pharmaceuticals
JAZZ
$16B
$89.2M 3.4%
571,936
+55,530
+11% +$8.55M
MRK icon
6
Merck
MRK
$316B
$88.6M 3.38%
+971,998
New +$86.2M
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$87.1M 3.32%
1,091,840
– –
RCUS icon
8
Arcus Biosciences
RCUS
$3.67B
$84.8M 3.23%
3,346,458
-84,552
-2% -$2.07M
HUM icon
9
Humana
HUM
$48.5B
$77.7M 2.97%
166,066
– –
PFE icon
10
Pfizer
PFE
$143B
$70.4M 2.69%
1,343,384
– –
BMRN icon
11
BioMarin Pharmaceuticals
BMRN
$11.6B
$69.6M 2.65%
839,371
+120,876
+17% +$9.62M
AVTR icon
12
Avantor
AVTR
$7.52B
$64.7M 2.47%
2,079,657
– –
UNH icon
13
UnitedHealth
UNH
$395B
$57.3M 2.19%
111,554
– –
IRTC icon
14
iRhythm Holdings
IRTC
$3.53B
$53.3M 2.03%
493,721
– –
AXSM icon
15
Axsome Therapeutics
AXSM
$12.1B
$52.1M 1.99%
+1,360,596
New +$43M
SGEN
16
DELISTED
Seagen Inc. Common Stock
SGEN
$50M 1.91%
+282,395
New +$40.7M
IQV icon
17
IQVIA
IQV
$33.3B
$48.1M 1.84%
221,696
– –
DVAX
18
DELISTED
Dynavax Technologies
DVAX
$47.9M 1.83%
3,805,370
– –
DHR icon
19
Danaher
DHR
$124B
$44.5M 1.7%
198,178
– –
QURE icon
20
uniQure
QURE
$2.72B
$41.7M 1.59%
2,236,370
+1,701,746
+318% +$27.1M
MOH icon
21
Molina Healthcare
MOH
$11.8B
$40.2M 1.53%
143,779
– –
VEEV icon
22
Veeva Systems
VEEV
$30.2B
$40.1M 1.53%
+202,387
New +$37.2M
ICUI icon
23
ICU Medical
ICUI
$3.98B
$39.8M 1.52%
242,185
+21,598
+10% +$4.16M
ARGX icon
24
argenx
ARGX
$54.3B
$39.7M 1.51%
+104,732
New +$33.7M
WAT icon
25
Waters Corp
WAT
$36.1B
$38.9M 1.49%
117,634
– –
1
2 3 4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
CPRC
Consolidated Portfolio Review Corp Woodbury, New York $1.1B AUM 8.96% 1-Year Est. Return
AWP
Abacus Wealth Partners Santa Monica, California $1.1B AUM 14.74% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

PFM Health Sciences's Q2 2022 Portfolio in Review

As of Q2 2022, PFM Health Sciences held 89 positions worth $2.62B, down 2% from $2.67B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

PFM Health Sciences deployed $108M of net new capital in Q2 2022, opening 20 new positions and adding to 21 existing holdings. Its largest new stake was Merck: 971,998 shares worth $88.6M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Syndax Pharmaceuticals, an estimated $24.4M trimmed.

  • PFM Health Sciences's largest Q2 2022 buy was Merck: 971,998 shares worth $88.6M.
  • PFM Health Sciences added most to uniQure in Q2 2022, an estimated $27.1M increase.
  • PFM Health Sciences's biggest Q2 2022 reduction was Syndax Pharmaceuticals, cutting an estimated $24.4M.
  • PFM Health Sciences fully exited Outset Medical in Q2 2022, selling an estimated $128M.
  • PFM Health Sciences's ten largest holdings make up 34% of its $2.62B portfolio in Q2 2022.
  • PFM Health Sciences opened 20 new positions and closed 10 in Q2 2022.
  • PFM Health Sciences's portfolio value fell 2% quarter-over-quarter to $2.62B.

Based on PFM Health Sciences's 13F filing for Q2 2022, filed 15 Aug 2022.